Why the study?
Does Avarol inhibit the expression of natural UAG suppressor glutamine tRNA in HTLV-IIIB-infected human H9 cells in vitro?
Does Avarol inhibit the expression of natural UAG suppressor glutamine tRNA in HTLV-IIIB-infected human H9 cells in vitro?
Avarol demonstrates antiviral activity in vitro by inhibiting the synthesis of a specific tRNA required for viral protease expression in HIV-infected cells.
Avarol shows in vitro HIV activity but should not change practice; leaves open tRNA suppression as a research target.
HTLV-IIIB-infected H9 cells are shown to contain a high level of the natural UAG suppressor glutamine tRNA(UmUG Gln); this tRNA has been demonstrated to be required for the synthesis of Moloney murine leukemia virus (Mo-MuLV)-encoded protease. After cultivation of HTLV-IIIB-infected H9 cells with Avarol at a concentration (1 microgram/ml), previously found to protect the cells against the cytopathic effects of HTLV-III, an almost complete inhibition of the synthesis of the tRNA(UmUG Gln) was observed. Moreover, we obtained some evidence that the processing of the HTLV-III precursor protein p53 to p24 is inhibited by Avarol in infected cells, suggesting that the compound interferes with the expression of the viral protease gene.
No takes yet. Share an insight, caveat, or question.
Müller et al. (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: